# An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

> **NCT02501629** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 177 (actual)

## Conditions studied

- Asthma
- Elevated Blood Eosinophils
- Oral Corticosteroid Dependence

## Interventions

- **DRUG:** Reslizumab
- **DRUG:** Placebo
- **DRUG:** Non-Oral Corticosteroid (non-OCS) Asthma Medication
- **DRUG:** Oral Corticosteroid (OCS)

## Key facts

- **NCT ID:** NCT02501629
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-29
- **Primary completion:** 2017-06-19
- **Final completion:** 2017-12-04
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2021-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02501629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02501629, "An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02501629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*